Vivo Opportunity Fund Holdings, L.P. - 10 Mar 2026 SCHEDULE 13G Report for AN2 Therapeutics, Inc. Common Stock, par value $0.00001 per share (ANTX)
- Filing Manager
- Vivo Opportunity Fund Holdings, L.P.
- Reporting Manager
- Vivo Opportunity Fund Holdings, L.P.
- Symbol
- ANTX
- Shares outstanding
- 35,804,325 shares
- Disclosed Ownership
- 2,864,346 shares
- Ownership
- 8%
- Form type
- SCHEDULE 13G
- Filing time
- 13 Mar 2026, 16:02:09 UTC
- Date of event
- 10 Mar 2026
- SEC
- View on sec.gov
Reporting Managers (4)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 8% | 2,864,346 | 2,864,346 | 0 | /s/ Kevin Dai | Kevin Dai/Managing Member of Vivo Opportunity, LLC, General Partner | |
| Vivo Opportunity, LLC | 8% | 2,864,346 | 2,864,346 | 0 | /s/ Kevin Dai | Kevin Dai/Managing Member | |
| Vivo Opportunity Cayman Fund, L.P. | 0.8% | 289,294 | 289,294 | 0 | /s/ Kevin Dai | Kevin Dai/Managing Member of Vivo Opportunity Cayman, LLC, General Partner | |
| Vivo Opportunity Cayman, LLC | 0.8% | 289,294 | 289,294 | 0 | /s/ Kevin Dai | Kevin Dai/Managing Member |